FTC Clears Bayer's Purchase of Conceptus

bayer logo conceptus acquisition
John MacDougal, AFP/Getty Images
NEW YORK -- The German drug company Bayer AG has received antitrust clearance from the Federal Trade Commission for its approximately $1.1 billion acquisition of Conceptus.

Bayer announced the deal last month, saying that it would help to expand the kinds of birth control it offers.

Mountain View, Calif.-based Conceptus Inc. (CPTS) makes Essure, an irreversible birth control method in which small metal and polyester coils are inserted to block a woman's fallopian tubes. The procedure can be done in 10 minutes in a doctor's office.

Bayer already markets birth control pills and intrauterine devices.

The transaction could be completed by midyear.


Increase your money and finance knowledge from home

Investor’s Toolbox

Improve your investing savvy with the right financial toolset.

View Course »

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Add a Comment

*0 / 3000 Character Maximum